In 1977, a research group in Basel isolated a small peptide from the cerebral venous blood of rabbits that had been put into deep sleep through low-frequency electrical stimulation of the thalamus. They named it delta-sleep-inducing peptide, or DSIP. Within a few years, researchers were testing it in humans, reporting improvements in insomnia with no apparent side effects, and speculating about its broader neurological roles.
Forty years later, DSIP remains one of the most studied and least understood regulatory peptides in neuroscience. It appears in the brain, the gut, the pituitary, and the blood. It affects sleep, stress hormones, pain, blood pressure, and epilepsy. It has been used as a medical product in Russia under the name Deltaran. And the scientific community still cannot fully agree on exactly how it works or why.
The Sleep Data
The human studies on DSIP and sleep, conducted primarily in the 1980s and early 1990s, are among the few clinical trials ever performed on this peptide. They are small by modern standards, but they are real and they are controlled.
A study in 6 middle-aged chronic insomniacs receiving intravenous DSIP at 25 nmol/kg found longer sleep duration, higher quality sleep with fewer interruptions, slightly more REM sleep, and no daytime sedation or side effects. The sleep-enhancing capacity was observed for up to 6 hours of night sleep. [Schneider-Helmert et al., PubMed, 1981]
A double-blind, placebo-controlled study in 14 chronic insomniacs receiving DSIP for 7 successive nights found substantial improvement in night sleep that accumulated with repeated doses. Sleep efficiency and daytime functioning reached levels comparable to healthy controls. [Schneider-Helmert, PubMed, 1984]
A third double-blind matched-pairs study in 16 chronic insomniacs found higher sleep efficiency and shorter sleep latency with DSIP compared to placebo, though the authors noted the effects were statistically modest and recommended further research. [Schneider-Helmert et al., PubMed, 1992]
The honest summary: DSIP improved sleep in human insomniacs in multiple controlled studies, with effect sizes that were real but not dramatic, and without any concerning side effects. That is a meaningful signal.
Beyond Sleep: A Peptide That Does Many Things
What makes DSIP genuinely puzzling is the breadth of its biological activity, much of which seems unrelated to sleep. According to published research, DSIP decreases basal corticotropin and blocks stress-related cortisol release, stimulates luteinizing hormone and growth hormone secretion, normalizes blood pressure and myocardial contraction, enhances oxidative phosphorylation efficiency in mitochondria, and has demonstrated anticonvulsant effects in epilepsy models. [Wikipedia DSIP entry, citing multiple primary sources]
The antinociceptive effects, meaning pain-reducing properties, have also been documented. In animal models, DSIP administered centrally produced potent pain relief. Its stress-protective and adaptive activity is of particular interest to researchers studying the physiology of chronic stress.
Neurological Recovery
A 2021 study published in Molecules examined intranasal DSIP administration in rats following focal stroke. After 8 days of treatment, DSIP-treated animals showed significantly accelerated recovery of motor functions compared to controls. The authors proposed DSIP as a candidate for post-stroke neurological recovery protocols. [Zarubina et al., MDPI Molecules, 2021]
This neurological recovery dimension adds a layer of clinical interest that goes well beyond sleep medicine. If DSIP can promote functional recovery after ischemic injury, the therapeutic implications are substantial.
Why Is This Not Better Known?
DSIP suffers from a combination of factors that have kept it at the margins of mainstream pharmacological research. Its half-life is short, its blood-brain barrier penetration is limited, and the early human studies, while positive, were small and conducted before modern clinical trial standards. The research has continued primarily in Russia and Eastern Europe, creating the same language and publication gap that affects Semax and Selank.
Recent work on fusion peptides combining DSIP with blood-brain barrier crossing sequences represents an attempt to solve the stability and delivery problems that limited earlier clinical work. If these formulation challenges can be addressed, DSIP may be due for a more serious evaluation in Western clinical settings.
The Bottom Line
DSIP is a real regulatory peptide with real published human data on sleep improvement and a fascinating range of neurological effects that extend well beyond its original name. It is not well understood, it is not widely used in Western medicine, and it has not been studied in the kind of large trials that would cement its clinical role.
What it represents is an interesting window into the body's endogenous regulatory chemistry: a peptide produced naturally during deep sleep that, when administered, appears to help restore the conditions it normally reflects.
This article is for informational purposes only and does not constitute medical advice.
Sources
1. Schneider-Helmert et al., PubMed, 1981 — PubMed 7028502
2. Schneider-Helmert, PubMed, 1984 — PubMed 3622582
3. Schneider-Helmert et al., PubMed, 1992 — PubMed 1299794
4. Zarubina et al., MDPI Molecules, 2021 — PMC8434407